ASOcura

ASOcura is a biopharmaceutical company specializing in the development of antisense oligonucleotide (ASO) drugs. Founded in 2017 by Yimin Hua, the principal inventor of Nusinersen, the company is headquartered in Suzhou, China.

The company's core focus is on creating therapies for rare, neurodegenerative diseases by targeting RNA splicing and RNA editing. Its drug development pipeline targets conditions such as Duchenne muscular dystrophy (DMD), spinocerebellar ataxia type 3 (SCA3), and Huntington's disease, aiming to provide effective treatments for patients with these spinal degenerative diseases.

ASOcura has secured significant funding to advance its research and clinical trials. In July 2023, it closed a pre-series A+ funding round with Herui Venture Capital. This was followed by a Series A funding round in July 2024, raising CNY 100 million from investors including SDIC Venture Capital. The company plans to use this capital to accelerate product development and apply for clinical trial registrations.

Keywords: antisense oligonucleotide, ASO drugs, neurodegenerative diseases, RNA splicing, RNA editing, Duchenne muscular dystrophy, spinocerebellar ataxia, Huntington's disease, drug development, biopharmaceutical, rare diseases, gene therapy, molecular science, clinical trials, pharmaceutical research, Suzhou, Yimin Hua